High-MPI scores correlated with poor overall survival, elevated tumor mutation burden (TMB), and an immunosuppressive TME, evidenced by reduced CD8+ T-cell infiltration and increased expression of immune checkpoints (PD-L1, TGF-β). The gene discussed is TGFB1; the disease is neoplasm.